ArticleAdvances in experimental medicine and biology2022
Nanomaterials, a New Challenge in the Workplace.
Article in Advances in experimental medicine and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 7 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomaterials are a nanotechnological product of increasing importance given the possibilities they offer to improve quality of life and support sustainable development. Safe management of nanomaterials is needed to ensure that this emerging technology has the highest levels of acceptance among different interest groups, including workers. This chapter reviews the current state that presents the different stages of risk management applied to nanomaterials, including standardisation, regulation, risk assessment and risk control. Particularly, the chapter contextualizes the development of nanotechnologies at European level and analyses the scientific evidence available on the risks derived from nanomaterials use. Furthermore, it highlights the required conditions to encourage the responsible development of nanomaterials, as well as reflects on the lack of consensus in terms of approaches and frameworks that could facilitate standardisation adoption, regulatory enforcement and industry intervention concerning nanomaterials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.